When was Dynavax founded?

Dynavax was founded in 1996 and raised its 1st funding round 3 years after it was founded.

Where is Dynavax located?

Dynavax is headquartered in Berkeley, United States. It is registered at Emeryville, California.

Who is the current CEO of Dynavax?

Ryan Spencer and Eddie Gray s of Dynavax.

How many employees does Dynavax have?

As of Aug 31, 2026, the latest employee count at Dynavax is 250.

Is Dynavax a funded company?

Dynavax is a funded company, having raised a total of $73.9M across 22 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Jul 13, 1999.

When was the latest funding round of Dynavax?

Dynavax's latest funding was a $***** Post IPO round on Aug 27, 2021, with participation from 1 investor.

What is the annual revenue of Dynavax?

Annual revenue of Dynavax is between $100M and $500M as on Dec 31, 2024

Where does Dynavax rank among its competitors?

Dynavax ranks 1st amongst 74 active competitors, of which 17 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was MAXVAX Biotechnology, which secured an undisclosed amount in Dec, 2025.

Who are the top competitors of Dynavax?

Dynavax's top competitors include Sinovac, VBI Vaccines and Ocugen. Among them, MAXVAX Biotechnology secured the most recent funding round in December, 2025.

Dynavax - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of products to prevent and treat infectious and inflammatory diseases and cancer. The lead candidate Heplisav-B Hepatitis B Vaccine combines TLR9 agonist and hepatitis B surface antigen. also developing DV2-HBV-25 for myocardial infarction, DV2-HBV-26 for immune-mediated herpes zoster, and others.

Website: www.dynavax.com/
Registered Address: Emeryville, California

Key Metrics

Founded Year

1996

Location

Berkeley, United States

Stage

Acquired

Total Funding

$73.9M in 22 rounds

Latest Funding Round

Post IPO, Aug 27, 2021, $*****

Investors

Axiom Venture Partners & 28 more

Ranked

1^st among 74 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2024

Employee Count

250 as on Aug 31, 2026

Investment & Acquisitions

Rhein Biotech

Similar Companies

Sinovac & 81 more

Exit Details

Acquired by Sanofi (Dec 24, 2025)

View Dynavax's full profile

Dynavax is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Dynavax GmbH CIN: 0797.887.554 , Belgium, Active	Jan 01, 2023	-	-	-
DYNAVAX TECHNOLOGIES CORP CIN: 1029142 , United States, Active	Nov 05, 2000	$100M - $500M (As on Dec 31, 2024)	408 (As on Dec 31, 2023)	-
Dynavax Technologies Corporation CIN: 330728374 , United States, Active	Dec 26, 999	-	258 (As on Dec 31, 2024)	-

Dynavax got acquired by Sanofi on Dec 24, 2025.

Click here to take a look at Dynavax's acquisition in detail

Dynavax has raised a total funding of $73.9M over 22 rounds. Its first funding round was on Jul 13, 1999. Its latest funding round was a Post IPO round on Aug 27, 2021 for $*****. 1 investor participated in its latest round. Dynavax has 29 institutional investors.

Here is the list of recent funding rounds of Dynavax:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 27, 2021	2955258	Post IPO	3130044	1040225	5802109	1877761
May 11, 2021	4936761	Post IPO	6740418	9598710	9335476	1905982
Mar 18, 2019	2691292	Conventional Debt	7587303	9112132	8897972	CRG

Access funding benchmarks and valuations. Sign up today!

View details of Dynavax's funding rounds and investors

Dynavax's employee count trend

Dynavax has 250 employees as of Aug 26. Here is Dynavax's employee count trend over the years:

Uncover Dynavax's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Dynavax include Sinovac, VBI Vaccines and Ocugen. Here is the list of Top 10 competitors of Dynavax, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Dynavax 1996, Berkeley (United States), Acquired	Developer of products to prevent and treat infectious and inflammatory diseases and cancer	$73.9M	Piper Jaffray, Bain Capital Life Sciences ... & 27 others	70/100
2nd	Sinovac 2001, Haidian (China), Acquired	Developer of vaccines against multiple infectious diseases	-	Vivo Capital, Sino Biopharmaceutical & 3 others	64/100
3rd	VBI Vaccines 2001, Cambridge (United States), Public	Developer of vaccines for the treatment of infectious diseases	$65.1M	RTW Investments, Perceptive Advisors & 7 others	60/100
4th	Ocugen 2013, Aurora (United States), Public	Developer of therapeutic solutions to treat various eye disorders	-	Checkmate Capital, Colorado Office of Economic Development and International Trade ... & 5 others	59/100
5th	HilleVax 2021, Boston (United States), Public	Developer of a vaccine for norovirus infection	$135M	Frazier Healthcare Partners, Perceptive Advisors ... & 11 others	57/100
6th	Sinopharm 2009, Beijing (China), Acquired	Developer of vaccines for infectious diseases	-	6 Dimensions Capital, Alpview Capital & 1 others	56/100
7th	Curevo 2017, Seattle (United States), Series B	Developer of non-mRNA adjuvanted subunit vaccines for infectious disease prevention	$196M	RA Capital Management, Janus Henderson Investors ... & 9 others	56/100
8th	Bavarian Nordic 1994, Hellerup (Denmark), Public	Developer of therapeutic vaccines against cancer and infectious diseases	-	Eiffel Investment Group, NB Capital & 1 others	56/100
9th	MAXVAX Biotechnology 2016, Lanzhou (China), Series D	Developer of vaccines for infectious diseases	$84.8M	Hillhouse, Korea Investment Partners & 10 others	54/100
10th	Cellevate 2014, Lund (Sweden), Seed	Developer of nanofiber-based cell culture products for upstream bioprocessing	$7.09M	Industrifonden, Smile Incubator & 3 others	53/100